Vascular News and Research

RSS

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

13 May 2010

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.

12 May 2010

$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

According to a new report by iData Research, the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.

11 May 2010

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Folic acid supplement may improve blood flow in young amenorrheic runners

A study led by sports medicine researcher Anne Hoch, D.O. at The Medical College of Wisconsin in Milwaukee has found that oral folic acid may provide a safe and inexpensive treatment to improve vascular function in young female runners who are amenorrheic (not menstruating).

11 May 2010

Aastrom Biosciences reports third quarter 2010 FY results

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported financial results for its third fiscal quarter ended March 31, 2010, and also announced progress in its late-stage clinical development programs and corporate operations.

11 May 2010

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

AngioDynamics announced today it has achieved the national launch of the newly redesigned Centros self-centering, chronic hemodialysis access catheter.

10 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

This week, TCA Cellular Therapy's Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific conference in San Diego.

7 May 2010

DJOFL net sales increases 10.3% to $240.1 million for first-quarter 2010

DJO Incorporated a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC ("DJOFL"), for the first quarter of 2010, ended April 3, 2010.

6 May 2010

Xience V sales out-performing Promus in Japanese drug-eluting stent market: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, when Abbott Vascular's Xience V and Boston Scientific's Promus entered the Japanese drug-eluting stent market in Q1 2010, both companies picked up share from competitors Medtronic and Cordis.

6 May 2010

AGA Medical first-quarter net sales increase 15.4% to $51.3 million

AGA Medical Holdings, Inc., a leading developer of interventional medical devices for the minimally invasive treatment of structural heart defects and vascular abnormalities, today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Whole grain barley products with low glycemic response provide favourable metabolic benefits

Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.

6 May 2010

Vascular News and Research

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

China Pharma first-quarter revenue up 16% to $15.1 million

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

Folic acid supplement may improve blood flow in young amenorrheic runners

Aastrom Biosciences reports third quarter 2010 FY results

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

DJOFL net sales increases 10.3% to $240.1 million for first-quarter 2010

Xience V sales out-performing Promus in Japanese drug-eluting stent market: MRG

AGA Medical first-quarter net sales increase 15.4% to $51.3 million

Whole grain barley products with low glycemic response provide favourable metabolic benefits

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News